Novo Nordisk Q1 Revenue Hits $15.2 Billion; Wegovy Pill Spurs Guidance Hike
Novo Nordisk reported first-quarter revenue of $15.17 billion and net income of $1.71 billion, delivering adjusted EPS of $1.04 and besting forecasts. Exceptional uptake of the newly launched Wegovy pill, fastest in weight-loss drug history, prompted a raise in its 2026 sales and profit guidance.
1. Q1 Financial Results
Novo Nordisk posted first-quarter revenue of $15.17 billion and net income of $1.71 billion, driving adjusted EPS of $1.04 and surpassing analyst estimates. Adjusted operating profit climbed to DKK 32,858 million, reflecting strong margin expansion across core markets.
2. Wegovy Pill Uptake
The newly launched Wegovy weight-loss pill achieved the fastest take-up in the category’s history, with initial sales far exceeding internal forecasts. Robust demand supported by targeted marketing and distribution channels underpinned a significant share of the revenue beat.
3. Updated 2026 Outlook
Buoyed by Wegovy’s performance, management raised full-year guidance for both adjusted sales and operating profit. The company signaled confidence in sustained double-digit growth in international operations driven by expanding obesity treatment adoption.